Article

Press Release

Karmanos Cancer Institute Opens Roseville Medical Oncology Clinic, Welcomes New Oncologist

The Barbara Ann Karmanos Cancer Institute is now seeing patients at the new Karmanos Cancer Institute – Roseville.

Tarik Hadid, MD, MPH, MS, FACP

Tarik Hadid, MD, MPH, MS, FACP

The Barbara Ann Karmanos Cancer Institute is now seeing patients at the new Karmanos Cancer Institute – Roseville. Located at 30550 Utica Road, this cancer center provides medical oncology services to patients in southern Macomb County. As the largest provider of cancer care and research in Michigan, the Roseville clinic becomes Karmanos’ 16th location.

“By extending our comprehensive cancer care to more communities, we are giving more patients access to their best chance to beat cancer,” said Brian Gamble, president of Karmanos Cancer Hospital in Detroit. “Recruiting and retaining the top oncologists and expanding our reach shows our commitment to increasing the availability of our expertise and tomorrow’s promising treatments.”

“The 6,000-square-foot location will offer clinical care, infusion and pharmacy services. Soon, patients will be able to receive chemotherapy treatments in clinic,” Gamble added. “As an extension of our headquarters and home base in Detroit, our specialists work to provide patients their best chance at a favorable outcome.”

Tarik Hadid, MD, MPH, MS, FACP, hematologist and medical oncologist, joins Karmanos and will primarily see patients for multiple types of cancer at the Roseville clinic.

“I am thrilled to join an NCI-designated comprehensive cancer center and provide world-class cancer care to more patients at the new clinic,” said Dr Hadid. “The level of care that Karmanos delivers is exceptional, and I look forward to bringing that same care to Roseville and surrounding communities. More importantly, our patients can focus on their healing instead of worrying about traveling long distances for the best cancer care.”

Dr Hadid has over a decade of experience treating multiple cancers, including lung, head and neck, thymic, mesothelioma and esophageal cancers. He is a member of Karmanos’ Head and Neck Oncology, Melanoma, Sarcoma, and Thoracic Oncology Multidisciplinary Teams (MDT), headquartered in Detroit. Much of his research focuses on conducting clinical and translational trials to improve treatment strategies for patients with head and neck and lung cancers. Through his research, Dr Hadid has conducted numerous clinical studies; published articles, case reports, abstracts and peer-to-peer-reviewed original works; and delivered multiple presentations. He is also a faculty member of the Hematology/Oncology Fellowship Program and associate professor at Wayne State University School of Medicine. Dr Hadid completed his residency in internal medicine, two fellowships in palliative medicine and hematology and oncology, and holds two master’s degrees in public health and science.

Ammar Sukari, MD, medical oncologist, leader of the Head and Neck Oncology MDT, and member of the Breast Cancer, Thoracic Oncology and Phase 1 Clinical Trials MDTs at Karmanos, will join Dr Hadid at the Roseville clinic. At this location, patients will have their treatments and surveillance appointments with one of the two physicians.

The Roseville clinic is the third cancer center Karmanos has opened in less than a year. The Karmanos Cancer Institute at The Toledo Clinic Cancer Center opened in April 2022, the first clinic outside Michigan. Karmanos completed the expansion of the Weisberg Cancer Center in Farmington Hills in October 2022 and celebrated the new Karmanos Cancer Institute at McLaren Greater Lansing in February 2022.

To learn more and schedule an appointment at Karmanos Cancer Institute – Roseville, visit karmanos.org/roseville or call 1-800-KARMANOS.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Jeffrey Zonder, MD
Jeffrey Zonder, MD
Abhinav Deol, MD